The BSF is proud to support a new set of clinical initiatives that hold great promise in the area of Meningioma treatment. Using BSF funds, investigators: Priscilla Brastianos, MD; Ian Dunn, MD; Sandro Santagata, MD, PhD; and Rameen Beroukhim, MD, PhD discovered novel recurrent mutations in Meningiomas that will have significant impact on the future treatment of these tumors. These mutations are known genetic targets in other cancer types but had never been described in Meningiomas until now. Dr. Brastianos has launched a far reaching, multi-institutional Phase II Study looking at inhibitors that target these mutations. This is the first ever trial of personalized drug therapies for Meningiomas, and represents a paradigm shift in Meningioma therapy!
To learn more about these trials, please click here to read the official NIH posting or visit brastianoslab.mgh.harvard.edu/. Patients who are interested in enrolling should share the NIH posting with their treating oncologist to determine eligibility.
The Brain Science Foundation is proud to support this groundbreaking study, and we hope our advocates will join us in supporting this work with your financial contribution to our Annual Appeal. Click here to make your secure, tax deductible contribution, or checks may be mailed to Brain Science Foundation, PO BOX 812701, Wellesley, MA 02482.